-
FDA initiates a CMC development and preparation pilot program to accelerate the development of CMC for investigational new drug application products
Time of Update: 2022-11-15
US FDA on October 31 A notice was issued in the Federal Register announcing the launch of the Chemistry, Manufacturing and Control (CMC) Development and Preparation Pilot (CDRP) program to facilitate the acceleration of products under investigational new drug (IND) applications if necessary, based on the expected clinical benefit of the product being obtained earlier by patients CMC development.
-
Oncolytic virus combined with PD-1/L1 antibody, the best partner or a magic weapon to break the bottleneck!
Time of Update: 2022-11-15
In 2022, an article was published in the American Journal of Translational Research titled Advances in the clinical development of oncolytic The research of viruses mainly describes the progress of oncolytic virus clinical research at home and abroad, and evaluates the safety and efficacy of oncolytic therapy for tumors.
-
The first generic was suspended from procurement, and the "patent war" of the original V.S. generic drug company continued
Time of Update: 2022-11-15
GGBI SOURCE drug patent radar Source: _msthash="320191" _msttexthash="88454847">Previously, on September 22, the Guangzhou Public Resources Exchange Center also issued an announcement, saying that in order to do a good job in the protection of intellectual property rights in the process of drug hanging online, the procurement platform of Guangzhou Pharmaceutical Group will suspend the qualification of linagliptin tablets (5mg, 7 tablets / box) of Guangdong East Sunshine Pharmaceutical Co.
-
Three innovative medical devices were approved by the NMPA "official announcement"
Time of Update: 2022-11-15
According to the official website of China's National Medical Products Administration (NMPA), three innovative medical devices were approved by the NMPA in October, including Abernoord's aspherical diffraction multifocal intraocular lens, Eco Medical's blood flow-directed dense mesh stent and Qianglian Zhichuang company's intracranial aneurysm surgery planning software.
-
Technical solution to the problem of purchasing subgroups of proprietary Chinese medicines and biological agents: Hebei once again enlightens us
Time of Update: 2022-11-15
In the price comparison table of the same group of proprietary Chinese medicines, the problems are divided into: different sources of bezoar musk, children's medication, whether it contains sugar, different groups with the same name, different names and the same side, different names, the same main side is slightly adjusted, and the dosage form is different (external use).
-
Has the valuation of the "water seller" bottomed out?
Time of Update: 2022-11-15
Secondly, after the market has a relatively full understanding of CRO companies in mid-2021, it began to worry about the marginal changes in the prosperity of this track, superimposed on the negative feedback formed by the long-term continuous adjustment of the industry as a whole, resulting in excessive trading pessimistic expectations under the inertia of digesting valuations.
-
FDA review inventory: 581 approvals in 14 years, which accelerated track is the most popular
Time of Update: 2022-11-15
On November 1, the Journal of the American Medical Association (JAMA) published a study analyzing FDA approvals for 581 new drug applications and new indications (including small molecules and biologics) between 2008 and 2021, including orphan drugs and non-orphan drugs, and found a significant increase in the proportion of new drug applications (including new indications) approved through the accelerated pathway process, and expects this growth trend to continue.
-
Huixin Biotech completed tens of millions of yuan in Pre-A round financing, committed to solving the bottleneck of exosome applications
Time of Update: 2022-11-15
Yang Yijie, general manager of Huixin Biotechnology, saidWeidu Venture Capital, the leading investment institution of this round, said that exosomes have shown great potential in the treatment, diagnosis and medical beauty repair of various complex diseases such as tumors and neurological diseases, and have broad application prospects.
-
What pushed Yan Ning to the first place in the hot search is the industry's expectation and hunger for basic research! Academicians "go down" to run a company, who is there? What are you doing?
Time of Update: 2022-11-15
Next, Yan Ning will do something that the domestic medical and scientific circles are looking forward to: serve as the founding president of the Shenzhen Academy of Medical Sciences, lead clinical, transformation and industrialization work, and promote the innovation of scientific research models.
-
Bi Jingquan: Biomedicine is one of the fields with the highest scientific and technological content and the most active investment
Time of Update: 2022-11-15
Bijing QuanBijing QuanDeputy Director of the Economic Committee of the National Committee of the Chinese People's Political Consultative ConferenceExecutive Vice Chairman of China Center for Internat
-
33 exclusive proprietary Chinese medicines are lit up! The two major varieties will break 1 billion for the first time, with Ling, Piazzai... Rising sharply, the "miracle medicine" fell incessantly
Time of Update: 2022-11-15
In 2022E, the total sales scale of 33 exclusive proprietary Chinese medicines with terminal sales of more than 300 million yuan in China's urban physical pharmacies is close to 20 billion yuan, a year-on-year increase of about 4.
-
Nature: 386 experts in 112 countries around the world propose the most effective measures to end the coronavirus public health threat
Time of Update: 2022-11-15
41 consensus statements and 57 recommendations communicate health systemsVaccination prevention and treatment to help outbreaks inequality vaccine+Top 10 recommendationsTop 10 recommendations Links to papers: Paper LinkEssay Link: Jeffrey Lazarus of the University of Barcelona in Spain and others have analysed lessons learned over the past three years to propose the most effective measures to end the coronavirus public health threat through a rigorous consensus-building approach.
-
The latest approval of the NMPA was released, and antidepressant class 1 new drugs and 2 heparin drugs were approved for marketing
Time of Update: 2022-11-14
Source: NMPA, listed company announcements, pharmaceutical cloud database, etc Heparin anticoagulation is an important part of the prevention and treatment of thromboembolic diseases, compared with unfractionated heparin, low molecular weight heparin has the advantages of definite anticoagulant effect, strong antithrombotic effect, less adverse reactions, high bioavailability, etc.
-
Behind the 95 million Chinese people suffering from depression, the tens of billions of antidepressant drug market is facing a reshuffle
Time of Update: 2022-11-14
"Antidepressant Drug Development and Domestic Market Analysis", Drug Times, 2021-4-22 Venlafaxine was developed by Wyeth (later acquired by Pfizer), approved by the FDA in December 1993, and entered the Chinese market in 2000.
-
Top 20 proprietary Chinese medicines! 12 exclusive varieties dominate the screen, 5 major brands rise by more than 10%, Yangtze River, Zuoli, Jimin credible... List
Time of Update: 2022-11-14
According to the latest data from Intranet, the sales scale of proprietary Chinese medicines in public hospitals in key cities in 2022H1 exceeded 15 billion yuan, and Beijing led the sales scale; Drug
-
Authoritative list: Biotech startups to watch in 2022 are here
Time of Update: 2022-11-14
Air companyPhytolonSepion TechnologiesTravertine TechnologiesZwitterco Micropep Technologies aims to reach the ceiling of the agricultural world – developing biological herbicides to selectively kill weeds that have a significant impact on crop growth.
-
From the perspective of R&D return rate, the sustainable growth of Chinese pharmaceutical companies
Time of Update: 2022-11-14
Since the second half of 2021, the pharmaceutical industry has been cold, and homogenized competition and the resulting price reduction of drugs have gradually lost confidence in the entire industry.
-
Wary! Zhong Nanshan and other academicians remind: this winter's flu + new crown epidemic risk is extremely high! The death rate of double infection has increased sharply by 2.4 times!
Time of Update: 2022-11-14
Three academicians, Chinese disease control reminds: this winter's flu + new crown epidemic risk is extremely high! Please pay attention!Three academicians, Chinese disease control reminds: this winte
-
Where will pandemic concept stocks go?
Time of Update: 2022-11-14
After azvudine, no new crown oral drug has been approved so far, which is partly because, according to the previous review criteria, the endpoint of the clinical trial is "Reducing the proportion of hospitalized or dying patients", and in an era of the Omicron pandemic and the vast majority of patients with mild disease, it is difficult to verify this effect.
-
The explosive procurement of domestic medical equipment has brought a superimposed effect, a main line of innovative drugs that benefit from the relaxation of policies
Time of Update: 2022-11-14
Therefore, the hemp essence drug market shows the characteristics of few players and a good competitive pattern, and has long been occupied by four major enterprises in the main market share, namely: Hengrui Pharmaceutical, Enhua Pharmaceutical, Renfu Pharmaceutical, and Yangtze River Pharmaceutical.
